Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock
Fundamentals
Source: third-party data provider, as of October 15, 2026
Compare with IKT
Recent news

New Strong Buy Stocks for February 13th
New Strong Buy Stocks for February 13th
IKT

New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 8th
IKT

Best Momentum Stocks to Buy for January 26th
Best Momentum Stocks to Buy for January 26th
IKT

New Strong Buy Stocks for January 26th
New Strong Buy Stocks for January 26th
IKT
Technical indicators
- RSI 14
- 31.55
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.11
- MACD histogram
- -0.02
- SMA 50
- $2.26
- Price below SMA 50
- EMA 50
- $2.13
- Price below EMA 50
- SMA 200
- $1.95
- Price below SMA 200
- EMA 200
- $1.96
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

New Strong Buy Stocks for February 13th
New Strong Buy Stocks for February 13th
IKT

New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 8th
IKT

Best Momentum Stocks to Buy for January 26th
Best Momentum Stocks to Buy for January 26th
IKT

New Strong Buy Stocks for January 26th
New Strong Buy Stocks for January 26th
IKT
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark T. Iwicki | CEO & Director | 1966 |
| Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer | 1970 |
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research & Development and Chief Medical Officer | 1969 |
| Dr. John Adams Ph.D. | Chief Scientific Officer | — |
| Mr. Jeffrey J. Kagy | Chief Human Resources Officer | — |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Development Operations | — |
| Mr. Timothy J. Pigot | Chief Commercial & Strategy Officer | 1971 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 15, 2026
Technical indicators
- RSI 14
- 31.55
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.11
- MACD histogram
- -0.02
- SMA 50
- $2.26
- Price below SMA 50
- EMA 50
- $2.13
- Price below EMA 50
- SMA 200
- $1.95
- Price below SMA 200
- EMA 200
- $1.96
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 14, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.50
- Average
- $1.50
- High
- $1.50
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +17.8 | -13.0 | +4.4 | -8.4 | +18.7 | +12.4 | +4.5 | -13.4 | -6.7 |



